Markus Steiner

Markus Steiner is affiliated with the Department of Internal Medicine III, specializing in Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology, and Oncologic Center research. His work focuses on immunotherapy, drug resistance mechanisms, and molecular pathways in cancers such as chronic lymphocytic leukemia (CLL) and colorectal carcinoma. He actively publishes in peer-reviewed journals and collaborates with international teams. His ORCID is 0000-0003-4424-6347.

Research interests include understanding MTOR signaling in CLL resistance, immune checkpoint modulation in MSI-H colorectal cancer, and biomarker development for targeted therapies. He also explores environmental applications of monoclonal antibodies, such as detecting diclofenac in water systems. His recent studies address challenges in phosphoproteomic analysis using CyTOF and genetic predictors of cancer treatment outcomes.

His contributions span case reports, reviews, and technical articles, with a focus on translating laboratory findings into clinical practice. He has presented at conferences and contributed to phase III clinical trials evaluating treatment efficacy.